Published in Pharm Res on January 01, 1998
Physiological parameters for oral delivery and in vitro testing. Mol Pharm (2010) 1.18
Predicting pharmacokinetics of drugs using physiologically based modeling--application to food effects. AAPS J (2009) 1.11
The use of biorelevant dissolution media to forecast the in vivo performance of a drug. AAPS J (2010) 1.01
Formulation, release characteristics and bioavailability study of oral monolithic matrix tablets containing carbamazepine. AAPS PharmSciTech (2008) 0.97
Hydrotropic polymer micelles containing acrylic acid moieties for oral delivery of paclitaxel. J Control Release (2008) 0.97
Synthesis, metabolism and cellular permeability of enzymatically stable dipeptide prodrugs of acyclovir. Int J Pharm (2008) 0.94
Intragastric floating drug delivery system of cefuroxime axetil: in vitro evaluation. AAPS PharmSciTech (2006) 0.93
Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling. Acta Pharmacol Sin (2012) 0.89
Drug absorption modeling as a tool to define the strategy in clinical formulation development. AAPS J (2008) 0.87
Human Gastrointestinal Juices Intended for Use in In Vitro Digestion Models. Food Dig (2011) 0.84
Ultra rapidly dissolving repaglinide nanosized crystals prepared via bottom-up and top-down approach: influence of food on pharmacokinetics behavior. AAPS PharmSciTech (2014) 0.84
The differences between the branded and generic medicines using solid dosage forms: In-vitro dissolution testing. Results Pharma Sci (2011) 0.84
Toward an in vivo dissolution methodology: a comparison of phosphate and bicarbonate buffers. Mol Pharm (2009) 0.83
Design and evaluation of self-nanoemulsifying drug delivery system of flutamide. J Young Pharm (2011) 0.83
Potential P-glycoprotein-mediated drug-drug interactions of antimalarial agents in Caco-2 cells. Am J Trop Med Hyg (2012) 0.83
A systematic approach to design and prepare solid dispersions of poorly water-soluble drug. AAPS PharmSciTech (2014) 0.81
Assessment of In Vivo Clinical Product Performance of a Weak Basic Drug by Integration of In Vitro Dissolution Tests and Physiologically Based Absorption Modeling. AAPS J (2015) 0.81
Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model. CPT Pharmacometrics Syst Pharmacol (2016) 0.80
Investigation of Thermal and Viscoelastic Properties of Polymers Relevant to Hot Melt Extrusion, IV: Affinisol™ HPMC HME Polymers. AAPS PharmSciTech (2015) 0.79
Development and validation of a discriminative dissolution test for betamethasone sodium phosphate and betamethasone dipropionate intramuscular injectable suspension. AAPS PharmSciTech (2013) 0.79
Evaluation of the membrane permeability (PAMPA and skin) of benzimidazoles with potential cannabinoid activity and their relation with the Biopharmaceutics Classification System (BCS). AAPS PharmSciTech (2011) 0.78
Application of ethylcellulose coating to hydrophilic matrices: a strategy to modulate drug release profile and reduce drug release variability. AAPS PharmSciTech (2014) 0.78
Surfactants modify the release from tablets made of hydrophobically modified poly (acrylic acid). Results Pharma Sci (2013) 0.77
Evaluation of nanosuspensions for absorption enhancement of poorly soluble drugs: in vitro transport studies across intestinal epithelial monolayers. AAPS J (2008) 0.76
Mechanistic prediction of food effects for Compound A tablet using PBPK model. Saudi J Biol Sci (2017) 0.75
Comparative in vitro and in vivo evaluation of three tablet formulations of amiodarone in healthy subjects. Daru (2010) 0.75
Nanocrystallization by evaporative antisolvent technique for solubility and bioavailability enhancement of telmisartan. AAPS PharmSciTech (2012) 0.75
The relevancy of controlled nanocrystallization on rifampicin characteristics and cytotoxicity. Int J Nanomedicine (2016) 0.75
Engineering and characterization of simplified vaginal and seminal fluid simulants. Contraception (2015) 0.75
Design of Potent and Orally Active GPR119 Agonists for the Treatment of Type II Diabetes. ACS Med Chem Lett (2015) 0.75
Crystalline nanosuspensions as potential toxicology and clinical oral formulations for BCS II/IV compounds. AAPS J (2012) 0.75
Mathematical Models to Explore Potential Effects of Supersaturation and Precipitation on Oral Bioavailability of Poorly Soluble Drugs. AAPS J (2015) 0.75
Release of a Poorly Soluble Drug from Hydrophobically Modified Poly (Acrylic Acid) in Simulated Intestinal Fluids. PLoS One (2015) 0.75
Physicochemical properties of dietary phytochemicals can predict their passive absorption in the human small intestine. Sci Rep (2017) 0.75
Role of medium-chain fatty acids in the emulsification mechanistics of self-micro-emulsifying lipid formulations. Saudi Pharm J (2014) 0.75
Statistical investigation of simulated fed intestinal media composition on the equilibrium solubility of oral drugs. Eur J Pharm Sci (2016) 0.75
Dissolution of pentoxifylline from extended release formulations. Researches concerning development of a biorelevant test. Curr Health Sci J (2009) 0.75
Performance Parameters and Characterizations of Nanocrystals: A Brief Review. Pharmaceutics (2016) 0.75
Development and evaluation of in situ gel of pregabalin. Int J Pharm Investig (2015) 0.75
A model for calcium permeation into small intestine. Biol Trace Elem Res (2010) 0.75
pH-Dependent Solubility and Dissolution Behavior of Carvedilol-Case Example of a Weakly Basic BCS Class II Drug. AAPS PharmSciTech (2015) 0.75
Controlled Suspensions Enable Rapid Determinations of Intrinsic Dissolution Rate and Apparent Solubility of Poorly Water-Soluble Compounds. Pharm Res (2017) 0.75
In vitro and in vivo evaluation of SN-38 nanocrystals with different particle sizes. Int J Nanomedicine (2017) 0.75
A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res (1995) 12.09
Methods to compare dissolution profiles and a rationale for wide dissolution specifications for metoprolol tartrate tablets. J Pharm Sci (1997) 2.35
The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm Res (1997) 2.28
Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur J Pharm Biopharm (2000) 2.14
Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res (1996) 2.05
Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm Res (1998) 1.88
Validation of bioanalytical methods. Pharm Res (1991) 1.83
5'-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm Res (1998) 1.66
Correlation of transient vision loss with outer retinal disruption following intravitreal ocriplasmin. Eye (Lond) (2013) 1.64
Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test. Clin Pharmacol Ther (1997) 1.64
In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. Eur J Pharm Sci (2000) 1.55
Review of global regulations concerning biowaivers for immediate release solid oral dosage forms. Eur J Pharm Sci (2006) 1.46
Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: permeabilities via diffusion, inside- and outside-directed carrier-mediated transport. J Pharm Sci (2000) 1.45
Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: verapamil hydrochloride, propranolol hydrochloride, and atenolol. J Pharm Sci (2004) 1.41
In-vitro dissolution profile comparison: statistics and analysis, model dependent approach. Pharm Res (1996) 1.36
Targeted prodrug design to optimize drug delivery. AAPS PharmSci (2000) 1.36
A compartmental absorption and transit model for estimating oral drug absorption. Int J Pharm (1999) 1.35
Parents' education and children's educational aspirations and achievements. Am Sociol Rev (1968) 1.27
Biowaiver monographs for immediate release solid oral dosage forms: ibuprofen. J Pharm Sci (2005) 1.26
Membrane topology of the human dipeptide transporter, hPEPT1, determined by epitope insertions. Biochemistry (1998) 1.23
Human postprandial gastric emptying of 1-3-millimeter spheres. Gastroenterology (1988) 1.23
Absorption potential: estimating the fraction absorbed for orally administered compounds. J Pharm Sci (1985) 1.21
The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; an explanation for the double peak phenomenon. J Pharmacokinet Biopharm (1987) 1.20
Moisture sorption kinetics for water-soluble substances. I: Theoretical considerations of heat transport control. J Pharm Sci (1983) 1.19
Cross-linking of gelatin capsules and its relevance to their in vitro-in vivo performance. J Pharm Sci (1994) 1.19
Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. Adv Drug Deliv Rev (1996) 1.17
Social class, parental encouragement, and educational aspirations. AJS (1968) 1.17
Prediction of physical aging in controlled-release coatings: the application of the relaxation coupling model to glassy cellulose acetate. Pharm Res (1991) 1.14
Topically applied antifungal agents. Percutaneous penetration and prophylactic activity against trichophyton mentagrophytes infection. Arch Dermatol (1977) 1.14
Influence of physical aging on mechanical properties of polymer free films: the prediction of long-term aging effects on the water permeability and dissolution rate of polymer film-coated tablets. Pharm Res (1991) 1.13
Griseofulvin levels in stratum corneum. Study after oral administration in man. Arch Dermatol (1972) 1.12
Scaleup of immediate release oral solid dosage forms. Pharm Res (1993) 1.10
Dissolution testing as a prognostic tool for oral drug absorption: dissolution behavior of glibenclamide. Pharm Res (2000) 1.09
Pharmacokinetics of trimethoprim and sulfamethoxazole in normal subjects and in patients with renal failure. J Infect Dis (1973) 1.08
Cellular uptake mechanism of amino acid ester prodrugs in Caco-2/hPEPT1 cells overexpressing a human peptide transporter. Pharm Res (1998) 1.07
Biowaiver monographs for immediate release solid oral dosage forms: acetaminophen (paracetamol). J Pharm Sci (2006) 1.07
Identification of formulation and manufacturing variables that influence in vitro dissolution and in vivo bioavailability of propranolol hydrochloride tablets. Pharm Dev Technol (1998) 1.06
HT29-MTX/Caco-2 cocultures as an in vitro model for the intestinal epithelium: in vitro-in vivo correlation with permeability data from rats and humans. J Pharm Sci (1996) 1.05
Novel approach to the analysis of in vitro-in vivo relationships. J Pharm Sci (1996) 1.03
Biowaiver monographs for immediate release solid oral dosage forms: ciprofloxacin hydrochloride. J Pharm Sci (2011) 1.03
Biology of membrane transport proteins. Pharm Res (1995) 1.02
Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: a mathematical model. Pharm Res (1993) 1.02
Protein denaturation during freezing and thawing in phosphate buffer systems: monomeric and tetrameric beta-galactosidase. Arch Biochem Biophys (2000) 1.02
The bioinequivalence of carbamazepine tablets with a history of clinical failures. Pharm Res (1992) 1.02
A thyromimetic that decreases plasma cholesterol levels without increasing cardiac activity. Nature (1987) 1.02
In-vitro release from corticosteroid ointments. J Pharm Sci (1995) 1.01
Assessment of value and applications of in vitro testing of topical dermatological drug products. Pharm Res (1999) 1.00
Bioequivalence of oral products and the biopharmaceutics classification system: science, regulation, and public policy. Clin Pharmacol Ther (2011) 1.00
Setting bioequivalence requirements for drug development based on preclinical data: optimizing oral drug delivery systems. J Control Release (1999) 0.98
Scale-up of adhesive transdermal drug delivery systems. Pharm Res (1997) 0.98
In vitro and in vivo assessment of adenovirus 41 as a vector for gene delivery to the intestine. Gene Ther (1998) 0.98
Biorelevant dissolution testing to predict the plasma profile of lipophilic drugs after oral administration. Pharm Res (2001) 0.98
Role of integrin expression in adenovirus-mediated gene delivery to the intestinal epithelium. Hum Gene Ther (1998) 0.98
A peptide prodrug approach for improving bisphosphonate oral absorption. J Med Chem (2000) 0.98
Predicting fraction dose absorbed in humans using a macroscopic mass balance approach. Pharm Res (1991) 0.98
Solubility of nonelectrolytes in polar solvents II: solubility of aliphatic alcohols in water. J Pharm Sci (1974) 0.97
Solubility of nonelectrolytes in polar solvents IV: nonpolar drugs in mixed solvents. J Pharm Sci (1976) 0.96
Topically applied griseofulvin in prevention and treatment of Trichophyton mentagrophytes. Arch Dermatol (1975) 0.95
Time-dependent oral absorption models. J Pharmacokinet Pharmacodyn (2001) 0.95
Membrane permeability parameters for some amino acids and beta-lactam antibiotics: application of the boundary layer approach. J Theor Biol (1988) 0.95
Dissolution of ionizable water-insoluble drugs: the combined effect of pH and surfactant. J Pharm Sci (2000) 0.95
Human proton/oligopeptide transporter (POT) genes: identification of putative human genes using bioinformatics. AAPS PharmSci (2000) 0.95
Absorption of polyethylene glycols 600 through 2000: the molecular weight dependence of gastrointestinal and nasal absorption. Pharm Res (1990) 0.94
Viscoelastic properties of polyacrylic acid gels in mixed solvents. Pharm Res (1992) 0.94
Determination of griseofulvin in skin, plasma, and sweat. J Pharm Sci (1972) 0.93
Correlation between epithelial cell permeability of cephalexin and expression of intestinal oligopeptide transporter. J Pharmacol Exp Ther (2001) 0.93
Characterization of the oral absorption of beta-lactam antibiotics. I. Cephalosporins: determination of intrinsic membrane absorption parameters in the rat intestine in situ. Pharm Res (1988) 0.93
Forecasting the in vivo performance of four low solubility drugs from their in vitro dissolution data. Pharm Res (1999) 0.93
Structural specificity of mucosal-cell transport and metabolism of peptide drugs: implication for oral peptide drug delivery. Pharm Res (1992) 0.93
Comparison of gastrointestinal pH in cystic fibrosis and healthy subjects. Dig Dis Sci (1987) 0.93
Saturable small intestinal drug absorption in humans: modeling and interpretation of cefatrizine data. Eur J Pharm Biopharm (1998) 0.93
Role of sweat in accumulation of orally administered griseofulvin in skin. J Clin Invest (1974) 0.93
Analysis of models for determining intestinal wall permeabilities. J Pharm Sci (1980) 0.92
Intestinal absorption mechanism of dipeptide angiotensin converting enzyme inhibitors of the lysyl-proline type: lisinopril and SQ 29,852. J Pharm Sci (1989) 0.92
A comparative study of different release apparatus in generating in vitro-in vivo correlations for extended release formulations. Eur J Pharm Biopharm (2009) 0.92
Bioequivalence of methylphenidate immediate-release tablets using a replicated study design to characterize intrasubject variability. Pharm Res (2000) 0.92
Scaleup of oral extended-release dosage forms. Pharm Res (1993) 0.92
Passive and carrier-mediated intestinal absorption components of captopril. J Pharm Sci (1988) 0.92
Characterization of the oral absorption of beta-lactam antibiotics. II. Competitive absorption and peptide carrier specificity. J Pharm Sci (1989) 0.92
Comparison of gastrointestinal pH in dogs and humans: implications on the use of the beagle dog as a model for oral absorption in humans. J Pharm Sci (1986) 0.92
Hydrops fetalis due to ABO incompatibility. Clin Pediatr (Phila) (1988) 0.91
Estimating drug solubility in the gastrointestinal tract. Adv Drug Deliv Rev (2007) 0.91
The relative bioavailability and in vivo-in vitro correlations for four marketed carbamazepine tablets. Pharm Res (1998) 0.91
Microultrafiltration technique for drug-protein binding determination in plasma. J Pharm Sci (1974) 0.91
Calculation of the aqueous diffusion layer resistance for absorption in a tube: application to intestinal membrane permeability determination. Pharm Res (1991) 0.91
Pharmacokinetics of probenecid following oral doses to human volunteers. J Pharm Sci (1982) 0.90
Human intestinal permeability of piroxicam, propranolol, phenylalanine, and PEG 400 determined by jejunal perfusion. Pharm Res (1997) 0.90
Overexpression of human intestinal oligopeptide transporter in mammalian cells via adenoviral transduction. Pharm Res (1998) 0.90
Modulated drug release using iontophoresis through heterogeneous cation-exchange membranes. 2. Influence of cation-exchanger content on membrane resistance and characteristic times. J Pharm Sci (1994) 0.90
CHO/hPEPT1 cells overexpressing the human peptide transporter (hPEPT1) as an alternative in vitro model for peptidomimetic drugs. J Pharm Sci (1999) 0.90
Biowaiver monographs for immediate release solid oral dosage forms: rifampicin. J Pharm Sci (2009) 0.90
Mixture experimental design in the development of a mucoadhesive gel formulation. Pharm Res (1991) 0.89
Biowaiver monographs for immediate release solid oral dosage forms: prednisolone. J Pharm Sci (2007) 0.89
Beta cyclodextrins enhance adenoviral-mediated gene delivery to the intestine. Pharm Res (1998) 0.89
Factors that influence stability of recombinant adenoviral preparations for human gene therapy. Pharm Dev Technol (1998) 0.89